Overview

An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)

Status:
Terminated
Trial end date:
2011-06-30
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to assess the long-term safety of lusutrombopag in the treatment of adults with relapsed persistent or chronic ITP with or without prior splenectomy.
Phase:
Phase 2
Details
Lead Sponsor:
Shionogi